The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.
Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance
Open accessAbstract
Epithelial to mesenchymal transition (EMT) contributes to tumor progression, cancer cell invasion, and therapy resistance. EMT is regulated by transcription factors such as the protein products of the SNAI gene family, which inhibits the expression of epithelial genes. Several signaling pathways, such as TGF-beta1, IL-6, Akt, and Erk1/2, trigger EMT responses. Besides regulatory transcription factors, RNA molecules without protein translation, micro RNAs, and long non-coding RNAs also assist in the initialization of the EMT gene cluster. A challenging novel aspect of EMT research is the investigation of the interplay between tumor microenvironments and EMT. Several microenvironmental factors, including fibroblasts and myofibroblasts, as well as inflammatory, immune, and endothelial cells, induce EMT in tumor cells. EMT tumor cells change their adverse microenvironment into a tumor friendly neighborhood, loaded with stromal regulatory T cells, exhausted CD8+ T cells, and M2 (protumor) macrophages. Several EMT inhibitory mechanisms are instrumental in reversing EMT or targeting EMT cells. Currently, these mechanisms are also significant for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Main EMT regulatory mechanisms. EMT is a product of internal and external events in cells. It is mainly induced by external factors, such as TGF-β1, neurotrophins, or interleukin-6, which activate several signaling pathways such as WNT, Smads, STATs, Akt, or Erk1/2. The activated pathways drive transcription factors (Goosecoid, Snail, Slug, Twist, nuclear factor erythroid-2-related factor 2 (NRF2), and Krüppel-like factors (KLFs)) to bind to special responding sequences in DNA, and, consequently, these mainly suppress the expression of genes related to epithelial differentiation. The best-known event in this process is the down-regulation of E-cadherin by the SNAI transcription factors, Snail, and Slug. At the same time, mesenchymal gene products, such as vimentin, are induced during the transcriptional changes in the EMT process, where the Smad, HIF-1α, and KLF4 transcription factors are directly involved [43,44]. The transcription regulatory process during EMT does not only rely on transcription factors, but also on long noncoding RNAs (lncRNAs) and microRNAs. The external EMT-inducing factors, such as TGF-β1, neurotrophins, or interleukin-6, are available from the fibroblastic and inflammatory microenvironment, but tumor cells also actively participate in the completion of an EMT program [45]. Based on the experimental data of several research groups, including ours, it has been found that acidic extracellular conditions and, in a further step, a low oxygen tension (hypoxia) are necessary for EMT. Interestingly, EMT tumor cells produce immune checkpoint regulatory molecules and actively remodel their immune microenvironment into a more tumor-friendly one from a hostile neighborhood.](https://figures.cochat.ai/paper-figures/d094b8bd283a4ef386664d3b8450b072/epithelial-to-mesenchymal-transition-a-mechanism-that-fuels-cancer-radio-figure-1.jpg)
![Figure 2 The TGF-β1 gradient causes heterogeneity in the tumor cell nests. There are higher TGF-β1 concentrations near the tumor vasculature, and the tumor cell nest has a decreasing gradient from its border towards the middle, which generates heterogeneity between the tumor–stroma interface and the tumor cell nest center [47]. The TGF-β1 gradient contributes to the heterogenic architecture of the tumor cell nest, where the invasive front has a completely different functional and differentiation profile than the core of the tumor cell nest. Additionally, at the invasive front, tumor cells interact with fibroblasts, leukocytes, and other stromal cells. Some scattered tumor cells undergo EMT at the tumor cell nest–stroma interface and contain both epithelial and mesenchymal markers. The figure is based on a figure published by Mayorca-Giuliani and Erler [48], which has been updated by the published data of Nieto et al. [29].](https://figures.cochat.ai/paper-figures/38bb690ce5c7436d87781e26d39438ba/epithelial-to-mesenchymal-transition-a-mechanism-that-fuels-cancer-radio-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include altered drug transport, e.g., overexpression of drug efflux pumps like ABC transporters, activation of cell survival signaling pathways such as PI3K/AKT, and deregulation of apoptotic pathways leading to resistance to apoptosis [76].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Tumor-associated chronic inflammation is a hallmark of cancer [72], which fosters the progression to metastasis [37].”
BackgroundNieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Cano, A., Pérez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., & Nieto, M. A. (2000) · Nature Cell Biology · doi:10.1038/35000025 · Cited by 3,668
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis
Yang, J., & Weinberg, R. A. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.05.009 · Cited by 3,012 · cited 1×
“The E-cadherin promoter is hypermethylated in leukemia, which leads to the loss of this protein [56], as in the tumor cells of solid tumors, which can lose E-cadherin by down-regulating EMT [24].”
BackgroundEMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · cited 1×
“Nevertheless, the EMT-TFs play even more important pleiotropic roles [4] in invasive, disseminating, and progressive cancer.”
BackgroundZheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032 · cited 4×
“One option to obtain better proof is the identification of EMT cells in tumor tissue sections by selective, reliable, and sensitive immunolabelling [30].”
BackgroundInfluentialBrabletz, T., Kalluri, R., Nieto, M. A., & Weinberg, R. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.118 · Cited by 1,961 · cited 9×
“Importantly, both directions of trans-differentiation are reactivated in many cancer types, but a full transition from an epithelial starting point into a differentiated fibroblastic endpoint with the expression of a fibroblast surface protein or vimentin is rarely executed [2,3].”
BackgroundInfluentialStructure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929 · cited 1×
“EMT cells overexpress the ABC transporters [97,98].”
Cited by
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
Huang, Y., Hong, W., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01347-8 · Cited by 1,032
Dynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 761
“EMT activation in these cells is controlling therapy resistance on multiple levels (Singh & Settleman, 2010; Shibue & Wein-berg, 2017; Santamaria et al , 2019; Dudas et al , 2020).”
InfluentialTargeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 625
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
Kumari, N., & Choi, S. H. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02272-x · Cited by 315
“Another mechanism underpinning chemoresistance has been discovered to be the epithelial to mesenchymal transition, which can be triggered by macrophages [101, 102].”
Background
Metadata
- Authors
- Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H.
- Affiliations
- Innsbruck Medical University (AT)
- National Institute of Oncology (HU)
- Corresponding author
- Dudás, József
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-02-12
- Volume
- 9
- Issue
- 2
- Pages
- 428
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7072371
- OpenAlex
- W3006507687
- Cited by
- 213
- References
- 137
- Citations by year
- 2026: 21 · 2025: 31 · 2024: 41 · 2023: 34 · 2022: 40 · 2021: 28 · 2020: 16
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Austrian Science Fund (P25869-B13, I3976-B33)
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (ANN 128524)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- epithelial-mesenchymal transition, cancer therapy resistance, radioresistance (biology), chemoresistance, TGF-β1 signaling, microRNA, long non-coding RNA, tumor microenvironment, cancer-associated fibroblasts, myofibroblasts, regulatory T cells, M2 macrophages, CD8+ T cell exhaustion, EMT reversal
- MeSH terms
- Antineoplastic Agents, Phytogenic, Humans, Neoplasms, Transcription Factors, Signal Transduction, Transforming Growth Factor beta, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase 3, T-Lymphocytes, Regulatory, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance. https://app.cochat.ai/papers/10.3390/cells9020428
- The paper
- Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H. (2020). Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance. Cells. https://doi.org/10.3390/cells9020428
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.